Immune Pharma (IMNP) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMNP Hot Sheet
Join SI Premium – FREE
Immune Pharma (NASDAQ: IMNP) reported Q4 EPS of ($0.27), $0.13 worse than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Immune Pharma (IMNP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HubSpot (HUBS) Tops Q3 EPS by 54c; offers guidance
- Aeva Technologies, Inc. (AEVA) Tops Q3 EPS by 4c
- Agilon Health Inc. (AGL) Tops Q3 EPS by 319c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
